📰 Medication Guide News
Page 43 - Medication Guide News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Medication Guide. Real-time updates on events, politics, business and more.
March 15, 2022
BOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), announced today that the National Comprehensive Cancer Network(R) (NCCN)
March 15, 2022
/PRNewswire/ -- New research from Memorial Sloan Kettering Cancer Center (MSK) led by medical oncologist Shari Goldfarb, MD, and colleagues, reports positive...
March 15, 2022
/PRNewswire/ -- New research from Memorial Sloan Kettering Cancer Center (MSK) led by medical oncologist Shari Goldfarb, MD, and colleagues, reports positive...
March 15, 2022
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous15.03.2022 / 21:01 The issuer is solely responsible for the content of this announcement.Media ReleaseNational Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology...
March 15, 2022
National Comprehensive Cancer Network® Updates Designation of Monjuvi® to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas BOSTON,... | March 15, 2022
March 11, 2022
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present research from its robust Alzheimers...
March 11, 2022
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present research from its robust Alzheimers...
March 11, 2022
Press release content from PR Newswire. The AP news staff was not involved in its creation.
March 11, 2022
AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. The collaboration is based on the results of preclinical research ...
March 11, 2022
CAMBRIDGE, Mass., March 11, 2022(Nasdaq: BIIB) announced the company will present new Alzheimer's disease research, as well as data for ADUHELM (aducanumab-avwa) injection 100 mg/mL for intravenous use